Health News

Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™ and Study Meets Primary Objective

Author: Australian Business

AMSTERDAM, The Netherlands, September 11, 2013 /PRNewswire/ -- ~ 67% survival demonstrated after 5 years and no transplant related mortalities ~ Manfred Ruediger, CEO of Kiadis Pharma, gives more information on ATIR™ and the five-year follow-up data in a video......

More...

More Articles...

PADRES Contra El Cáncer se une a Verizon y AEG para la 13ª gala anual de PADRES Contra El Cáncer
PADRES Contra El Cancer Is Teaming Up With Verizon And AEG For PADRES Contra El Cancer's 13TH Annual Fundraising Gala
ViSalus® Announces Tara Wilson as New Diamond Ambassador
Intersurgical, ERDRICH Umformtechnik, Bridgestone Collaborates with Changzhou National Hi-Tech District
California Senate Passes Bill Allowing Direct Access to Physical Therapist Services
SI-BONE, Inc. passe le cap des 25 000 implants iFuse
SI-BONE, Inc. annuncia il raggiungimento di 25.000 impianti iFuse
MD Stem Cells Begins the Largest Stem Cell Eye Treatment Study to Date
Family Research Council Calls on House to Oppose Rule on Continuing Resolution, Urges Defunding Obamacare
Timely topics, powerful speakers highlight Women's Leadership Conference at Mount St. Mary's College

Page 1842 of 1906